Pre-GMP Facility
Bridge to Translation - Immunotherapy from Bench to Bed side
![Image without a title](https://cdn.lmu-klinikum.de/861efe2b2313e079/b85b618f3d98/v/ef13addcab1a/DSC00828.jpg)
Cellular immunotherapy requires the set-up of GMP-compatible procedures. The transfer of experimental methods to clinical scale cell engineering includes
- Automation and up-scale of cell product manufacturing
- Set-up and validation of quality control
- Product characterization
- Pre-clinical data finalization for Clinical Trial Submission
![Image without a title](https://cdn.lmu-klinikum.de/74849db1aebed2d4/c4a9d251af45/v/e3b1a0dd7639/Elektroporator2.1.jpg)
For clinical scale cell engineering in a functionally closed system we chose the "CliniMACS Prodigy" device. It offers a platform for GMP-grade cell processing applications enabling fully automated washing, fractionation, cultivation, transduction and magnetic seperation of cells in a functionally closed system.
The platform´s flexibility allows production of a wide range of cell products under S2 conditions. Further, automation within this device allows harmonization of cell-production processes in case of multicentric production strategies in clinical studies.
With the electroporator "GTx" (MaxCyte) we also have a GMP-compatible platform for the production of CRISPR/Cas-engineered cell therapy products, which can be combined with our existing platform via a tube system. The new range of non-viral "genetic engineering" processes enables the development of a wide variety of innovative T-cell therapy approaches.
Set-up of the GMP-conform manufacturing process includes generation of SOP, selection of GMP-compatible reagents and up-scale of lab protocols. Pre-validation runs are performed in order to establish the manufacturing process, train staff and prepare production approval.
"MACSQuant Analyzer" offers a GCP-compatible high-throughput platform for flow-cytometry-based quality control. With a range of automated features, this flow cytometer lays the foundation for standardization of analysis and gating procedures.
- Absolute quantification of cell populations allows dosing of cell products
- Automation allows harmonization and standardization of quality control analyses in case of multicentric production
- Development of MACSQuant "Express Modes" offers fast and easy quality control analyses
Quality control strategies are set-up and validated in accordance to the requirements of regulatory authorities.
![Image without a title](https://cdn.lmu-klinikum.de/be284d42aded6fea/9caf8a4f8c2d/v/78cc47a36045/MACSQuant-Analyzer-10_bearbeitet_TA_01.jpg)
![Image without a title](https://cdn.lmu-klinikum.de/20a586e0519a53e7/f8f752a2d9d9/v/e7eaf282c8f6/DSC00788.jpg)
According to regulatory requirements cell products are pre-clinically characterized using established validation processes and infrastructures:
- Specificity
- Purity
- Potency
- Identity
Standardly, stability assays are perfomed in order to determine the shelf-life of the cell products.
![Image without a title](https://cdn.lmu-klinikum.de/6bd233130b3a37df/a687b5c4d19d/v/1960051598db/TK_white.jpg)
Dr. Theresa Kaeuferle
Head of Pre-GMP Facility
Executive Management
✉ Theresa.Kaeuferle@med.uni-muenchen.de
☎ 089-4400-52338
![Image without a title](https://cdn.lmu-klinikum.de/bca71fb38cb719a0/5765cf22b63d/v/580f2bf8c09a/Dr.-Ramona-Krauss.jpg)
Dr. Ramona Krauß
Regulatory Affairs, Ethics and Biobanking
✉ Ramona.Krauss@med.uni-muenche.de
☎ 089-4400-52759
![Image without a title](https://cdn.lmu-klinikum.de/c317384ebbe453d8/b144d777785d/v/0552df0ff6f9/Christina-Dietzer-Foto.jpg)
![Image without a title](https://cdn.lmu-klinikum.de/0abca71ef2648af3/3a1c4f44c1c9/v/183dd2224616/Teresa-Augustin_2021_Unschaerfe.jpg)
![Image without a title](https://cdn.lmu-klinikum.de/6d32d4958f2a9f11/dd50ba1cf77a/v/8ded1a15ba3c/TF_white_feuchtinger.jpg)
Prof. Tobias Feuchtinger
Dr. von Hauner Children´s Hospital
Head of Haematology/Oncology Department
✉ Kinderkrebszentrum@med.uni-muenchen.de
☎ 089-4400-52759
![Image without a title](https://cdn.lmu-klinikum.de/82d0dec933ad05a4/37f43f7ac4fc/v/4c476f6acfbf/Mira_bearbeitet_01.jpg)
![Image without a title](https://cdn.lmu-klinikum.de/58c61d64e064d806/ea101935f47b/v/a159efd242b8/Lena-Jablonowski_2021_Unschaerfe.jpg)
Lena Jablonowski
Doctoral Researcher (PhD track)
✉ Lenamaria.Jablonowski@med.uni-muenchen.de
☎ 089-4400-57791
![Image without a title](https://cdn.lmu-klinikum.de/5615950760a9e6f3/1ad1ccf9d230/v/de53477d3588/Max_Zwermann_2022.jpg)
Maximilian Zwermann
Doctoral Researcher (MD track)
✉ Maximilian.Zwermann@med.uni-muenchen.de
☎ 089-4400-57790
- 2 Patent Applications
- Kaeuferle T et al. Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells. Clin. Transl. Immunol. 2022 Jan 11:e1372. doi: 10.1002/cti2.1372
- Stief TA, Kaeuferle T, Müller TR et al. Protective T-cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021 May 28:S1525-0016(21)00303-8. doi: 10.1016/j.ymthe.2021.05.021
- Kaeuferle T et al. CRISPR-Cas9-Mediated Glucocortioid Resistance in Virus-Specific T cells for Adoptive T Cell Therapy Posttransplantation. Mol Ther. 2020 Jun 11:S1525-0016(20)30292-6. doi: 10.1016/j.ymthe.2020.06.002.
- Kaeuferle T et al. Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J Hematol Oncol. 2019 Feb 6:12(1):13. doi: 10.1186/s13045-019-0701-1
Contact:
Dr. Theresa Käuferle
Head of Pre-GMP Facility
Dr. von Hauner Children´s Hospital
Dep. of Haematology/Oncology
Tel.: 089/4400-52338